Unlock instant, AI-driven research and patent intelligence for your innovation.
Application of fingolimod and its structural analog in preparation of cerebral hemorrhage treatment medicines
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology with similar structure and fingolimod hydrochloride, applied in the field of fingolimod and its structural analogs, can solve problems such as no cerebral hemorrhage, and achieve the effects of expanding clinical indications, highlighting promotion prospects, and achieving remarkable curative effects
Inactive Publication Date: 2014-11-26
施福东 +10
View PDF0 Cites 2 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0004] In the prior art, fingolimod is only used to treat multiple sclerosis, and there is no application of this drug in the treatment of cerebral hemorrhage
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0024] 1. Preparation of drugs
[0025] Take 50g of fingolimod and 2450g of starch, mix 950g of starch with water to make a thin slurry, then gradually add the remaining starch and all of fingolimod to the slurry under stirring, stir all the ingredients evenly, make granules, and then Sieve, dry, and pack into capsules.
[0026] 2. Selection of experimental objects
[0027] Between March 2013 and December 2013, 11 patients with spontaneous subtentorial parenchymal hemorrhage with onset time less than 72 hours, hematoma volume between 5ml and 30ml, Glasgow coma index not less than 6, and no heart rhythm Patients with abnormalities, macular edema, tumors and immunosuppressants were used as experimental subjects, and 12 people were matched with clinical and imaging characteristics as controls.
[0028] 3. Experimental method
[0029] Patients were divided into fingolimod treatment group and control group, the control group received standard cerebral hemorrhage treatment; fingo...
Embodiment 2
[0042] Take 50g of fingolimod and 2450g of starch, mix 950g of starch with water to make a thin slurry, then gradually add the remaining starch and all of fingolimod to the slurry under stirring, stir all the ingredients evenly, make granules, and then Sieve and dry to form granules.
Embodiment 3
[0044] Take 50g of fingolimod, 2300g of starch, and 150g of magnesiumstearate, mix 950g of starch and water to make a thin slurry, and then gradually add the remaining starch, all of fingolimod and all of the stearin to the slurry while stirring Magnesium acid, all stirred evenly, dried and compressed into tablets, film-coated to form tablets.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention provides a new use of fingolimod and its structural analog in the preparation of cerebral hemorrhage treatment medicines, and further clarifies a treatment mechanism, an effective dosage, a suitable dosage form, and a concrete compound referred to the structural analog. Experiments prove that fingolimod and its structural analog can alleviate lymphocyte infiltration caused by cerebral hemorrhage, and the above alleviation effect can be used as a new cerebral hemorrhage target in order to determine the new use of the fingolimod and its structural analog in the preparation of cerebral hemorrhage treatment medicines based on the above property of the fingolimod and its structural analog. The clinic adaptationdisease of the fingolimod and its structural analog is enlarged, and the participation of immune cells in the pathologicallesion of the cerebral hemorrhage is disclosed. The medicines prepared in the invention have a substantial curative effect on the cerebral hemorrhage, and have a protruding popularization prospect.
Description
technical field [0001] The present invention relates to a new application of fingolimod and its structural analogues, in particular to an application of fingolimod and its structural analogues in the preparation of medicaments for treating cerebral hemorrhage. Background technique [0002] Cerebral hemorrhage is a common clinical disease with high morbidity and mortality rates. The current conventional treatment methods are surgical therapy and drug supportive therapy. Among them, surgical therapy is an effective treatment method generally recognized in the technical field. However, due to the limitations of factors such as its high risk, high cost, and high physical requirements for patients, the scope of use has been affected. At present, the main mechanism of drug supportive therapy includes dehydration, lowering intracranial pressure, lowering blood sugar, lowering lipids, etc., all of which are indirect effects, and their curative effects are not exact. To sum up, ther...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More